These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

858 related articles for article (PubMed ID: 8908498)

  • 1. Comparison of IL-2- and IL-4-transfected B16-F10 cells with a novel oil-microemulsion adjuvant for B16-F10 whole cell tumour vaccine.
    Souberbielle BE; Knight BC; Morrow WJ; Darling D; Fraziano M; Marriott JB; Cookson S; Farzaneh F; Dalgleish AG
    Gene Ther; 1996 Oct; 3(10):853-8. PubMed ID: 8908498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of cytokine gene transfection may differ for autologous and allogeneic tumour cell vaccines.
    Todryk SM; Birchall LJ; Erlich R; Halanek N; Orleans-Lindsay JK; Dalgleish AG
    Immunology; 2001 Feb; 102(2):190-8. PubMed ID: 11260324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNgamma primed and IFNbeta treated B7-1+ B16-F10 melanoma cells.
    Dezfouli S; Hatzinisiriou I; Ralph SJ
    Immunol Cell Biol; 2003 Dec; 81(6):459-71. PubMed ID: 14636243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of four strategies for tumour vaccination in the B16-F10 melanoma model.
    Souberbielle BE; Westby M; Ganz S; Kayaga J; Mendes R; Morrow WJ; Dalgleish AG
    Gene Ther; 1998 Nov; 5(11):1447-54. PubMed ID: 9930297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomes containing interferon-gamma as adjuvant in tumor cell vaccines.
    van Slooten ML; Storm G; Zoephel A; Küpcü Z; Boerman O; Crommelin DJ; Wagner E; Kircheis R
    Pharm Res; 2000 Jan; 17(1):42-8. PubMed ID: 10714607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine.
    Yei S; Bartholomew RM; Pezzoli P; Gutierrez A; Gouveia E; Bassett D; Soo Hoo W; Carlo DJ
    Gene Ther; 2002 Oct; 9(19):1302-11. PubMed ID: 12224013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model.
    Gupta S; Termini JM; Rivas Y; Otero M; Raffa FN; Bhat V; Farooq A; Stone GW
    Vaccine; 2015 Sep; 33(38):4798-806. PubMed ID: 26241951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to freund's complete adjuvant, but continues to induce T helper 2 cytokine production.
    Brewer JM; Conacher M; Satoskar A; Bluethmann H; Alexander J
    Eur J Immunol; 1996 Sep; 26(9):2062-6. PubMed ID: 8814247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced tumorigenicity of B16-F10 mouse melanoma cells transfected with mycobacterial antigen 85A.
    Tarrant JP; Walsh MJ; Blanchard MC; Lee TD; Hoskin DW; Giacomantonio CA
    Int J Oncol; 2004 Dec; 25(6):1693-9. PubMed ID: 15547707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine.
    Kayaga J; Souberbielle BE; Sheikh N; Morrow WJ; Scott-Taylor T; Vile R; Chong H; Dalgleish AG
    Gene Ther; 1999 Aug; 6(8):1475-81. PubMed ID: 10467372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of paracrine immunotherapy in experimental brain tumors.
    Lesniak MS; Sampath P; DiMeco F; Viglione MP; Tyler BM; Pardoll DM; Brem H
    Neurosurg Focus; 2000 Dec; 9(6):e4. PubMed ID: 16817687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new mouse model of experimental melanoma for vaccine and lymphokine therapy.
    Shrayer DP; Bogaars H; Wolf SF; Hearing VJ; Wanebo HJ
    Int J Oncol; 1998 Aug; 13(2):361-74. PubMed ID: 9664134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The biological effects of syngeneic and allogeneic cytokine-expressing prophylactic whole cell vaccines and the influence of irradiation in a murine melanoma model.
    Labarthe MC; Halanek N; Birchall L; Russell N; Desel C; Todryk S; Peters MJ; Lucas A; Falkenberg FW; Dalgleish AG; Whelan M; Ward SJ
    Cancer Immunol Immunother; 2006 Mar; 55(3):277-88. PubMed ID: 16158275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells.
    Abdel-Wahab Z; Dar MM; Hester D; Vervaert C; Gangavalli R; Barber J; Darrow TL; Seigler HF
    Cell Immunol; 1996 Aug; 171(2):246-54. PubMed ID: 8806794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization of mice with irradiated melanoma tumor cells transfected to secrete lymphokines and coupled with IL-2 or GM-CSF therapy.
    Shrayer DP; Bogaars H; Hearing VJ; Wanebo HJ
    J Exp Ther Oncol; 1996 Mar; 1(2):126-33. PubMed ID: 9414396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases.
    Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
    Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of a systemic immune response by a polyvalent melanoma-associated antigen DNA vaccine for prevention and treatment of malignant melanoma.
    Tanaka M; Kaneda Y; Fujii S; Yamano T; Hashimoto K; Huang SK; Hoon DS
    Mol Ther; 2002 Mar; 5(3):291-9. PubMed ID: 11863419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation.
    García-Hernández ML; Hernández-Pando R; Gariglio P; Berumen J
    Immunology; 2002 Feb; 105(2):231-43. PubMed ID: 11872099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.
    Oniki S; Nagai H; Horikawa T; Furukawa J; Belladonna ML; Yoshimoto T; Hara I; Nishigori C
    Cancer Res; 2006 Jun; 66(12):6395-404. PubMed ID: 16778218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic murine melanoma cell vaccine: a model for the development of human allogeneic cancer vaccine.
    Knight BC; Souberbielle BE; Rizzardi GP; Ball SE; Dalgleish AG
    Melanoma Res; 1996 Aug; 6(4):299-306. PubMed ID: 8873049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.